Akero Net Income Applicable To Common Shares from 2010 to 2024
| AKRO Stock | USD 32.17 1.01 3.24% |
Net Loss | First Reported 2017-12-31 | Previous Quarter -25.8 M | Current Value -31.1 M | Quarterly Volatility 13.7 M |
Check Akero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akero Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 3.3 M or Selling General Administrative of 16.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.41. Akero financial statements analysis is a perfect complement when working with Akero Therapeutics Valuation or Volatility modules.
Akero | Net Income Applicable To Common Shares |
Latest Akero Therapeutics' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Akero Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Akero Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Akero Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (44,426,471) | |
| Coefficient Of Variation | (103.58) | |
| Mean Deviation | 41,919,075 | |
| Median | (5,211,272) | |
| Standard Deviation | 46,016,303 | |
| Sample Variance | 2117.5T | |
| Range | 106.8M | |
| R-Value | (0.89) | |
| Mean Square Error | 464.7T | |
| R-Squared | 0.80 | |
| Slope | (9,181,425) | |
| Total Sum of Squares | 29645T |
Akero Net Income Applicable To Common Shares History
About Akero Therapeutics Financial Statements
Akero Therapeutics investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Akero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -100.8 M | -105.9 M |
Pair Trading with Akero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akero Stock
| 0.76 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Akero Stock
| 0.8 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.77 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.76 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.66 | PEPG | PepGen | PairCorr |
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Akero Therapeutics Correlation against competitors. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.